CD33 and acute myeloid leukemia: For example, Mylotarg (Gemtuzumab Ozogamicin), which was initially approved for the treatment of CD33-positive acute myeloid leukemia (AML) in 2001 [44], withdrew from the market in 2010 due to severe toxicity [39, 45].